Evolution AB (publ)
F:E3G1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Evolution AB (publ)
F:E3G1
|
SE |
|
A
|
Accelerate Diagnostics Inc
LSE:0H8E
|
US |
|
Cigniti Technologies Ltd
NSE:CIGNITITEC
|
IN |
|
88 Energy Ltd
ASX:88E
|
AU |
|
P
|
Pathfinder Ventures Inc
XTSX:RV
|
CA |
|
Orix Corp
NYSE:IX
|
JP |
|
C
|
Card Factory PLC
OTC:CRFCF
|
UK |
|
Koninklijke BAM Groep NV
AEX:BAMNB
|
NL |
|
Consolidated Edison Inc
NYSE:ED
|
US |
|
AN2 Therapeutics Inc
NASDAQ:ANTX
|
US |
Wall St Price Targets
E3G1 Price Targets Summary
Evolution AB (publ)
According to Wall Street analysts, the average 1-year price target for E3G1 is 59.02 EUR with a low forecast of 45.2 EUR and a high forecast of 97.7 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is E3G1's stock price target?
Price Target
59.02
EUR
According to Wall Street analysts, the average 1-year price target for E3G1 is 59.02 EUR with a low forecast of 45.2 EUR and a high forecast of 97.7 EUR.
What is the Revenue forecast for Evolution AB (publ)?
Projected CAGR
6%
Over the last 12 years, the compound annual growth rate for Revenue has been 40%. The projected CAGR for the next 8 years is 6%.
What is the Operating Income forecast for Evolution AB (publ)?
Projected CAGR
6%
Over the last 12 years, the compound annual growth rate for Operating Income has been 51%. The projected CAGR for the next 8 years is 6%.
What is the Net Income forecast for Evolution AB (publ)?
Projected CAGR
10%
Over the last 12 years, the compound annual growth rate for Net Income has been 52%. The projected CAGR for the next 8 years is 10%.
